Home/Pipeline/NA-731

NA-731

Traumatic Brain Injury

Phase 2AActive

Key Facts

Indication

Traumatic Brain Injury

Phase

Phase 2A

Status

Active

Company

Biomed

About Biomed

Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.

View full company profile

Therapeutic Areas

Neurological Diseases Metabolic Disorders Cardiovascular Diseases Rare Diseases

Other Traumatic Brain Injury Drugs

Drug	Company	Phase	Status
Presendin™ (Exenatide)	Invex Therapeutics	Preclinical	Active
TBI Modeling Platform	bmseed	Research Tool	Active
TV-301	TheraVac Biologics	Preclinical	Active
TBI Indication	Hera Health Solutions	Proof of Concept/Bench Validation	Active
Fv-Hsp72 for TBI	Rubicon Biotechnology	Pre-clinical	Active
TBI Treatment System	Vivonics	Development/Testing	Active
Traumatic Brain Injury (TBI) Implant	Matricelf	Preclinical	Active